Literature DB >> 18199855

Cumulative association of five genetic variants with prostate cancer.

S Lilly Zheng1, Jielin Sun, Fredrik Wiklund, Shelly Smith, Pär Stattin, Ge Li, Hans-Olov Adami, Fang-Chi Hsu, Yi Zhu, Katarina Bälter, A Karim Kader, Aubrey R Turner, Wennuan Liu, Eugene R Bleecker, Deborah A Meyers, David Duggan, John D Carpten, Bao-Li Chang, William B Isaacs, Jianfeng Xu, Henrik Grönberg.   

Abstract

BACKGROUND: Single-nucleotide polymorphisms (SNPs) in five chromosomal regions--three at 8q24 and one each at 17q12 and 17q24.3--have been associated with prostate cancer. Each SNP has only a moderate association, but when SNPs are combined, the association may be stronger.
METHODS: We evaluated 16 SNPs from five chromosomal regions in a Swedish population (2893 subjects with prostate cancer and 1781 control subjects) and assessed the individual and combined association of the SNPs with prostate cancer.
RESULTS: Multiple SNPs in each of the five regions were associated with prostate cancer in single SNP analysis. When the most significant SNP from each of the five regions was selected and included in a multivariate analysis, each SNP remained significant after adjustment for other SNPs and family history. Together, the five SNPs and family history were estimated to account for 46% of the cases of prostate cancer in the Swedish men we studied. The five SNPs plus family history had a cumulative association with prostate cancer (P for trend, 3.93x10(-28)). In men who had any five or more of these factors associated with prostate cancer, the odds ratio for prostate cancer was 9.46 (P=1.29x10(-8)), as compared with men without any of the factors. The cumulative effect of these variants and family history was independent of serum levels of prostate-specific antigen at diagnosis.
CONCLUSIONS: SNPs in five chromosomal regions plus a family history of prostate cancer have a cumulative and significant association with prostate cancer. Copyright 2008 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199855     DOI: 10.1056/NEJMoa075819

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  285 in total

1.  Genetic variants associated with patent ductus arteriosus in extremely preterm infants.

Authors:  John M Dagle; Kelli K Ryckman; Cassandra N Spracklen; Allison M Momany; C Michael Cotten; Joshua Levy; Grier P Page; Edward F Bell; Waldemar A Carlo; Seetha Shankaran; Ronald N Goldberg; Richard A Ehrenkranz; Jon E Tyson; Barbara J Stoll; Jeffrey C Murray
Journal:  J Perinatol       Date:  2018-12-05       Impact factor: 2.521

2.  Germ-line sequence variants of PTEN do not have an important role in hereditary and non-hereditary prostate cancer susceptibility.

Authors:  Chunmei C Xie; Lingyi Lu; Jielin Sun; S Lilly Zheng; William B Isaacs; Henrik Gronberg; Jianfeng Xu
Journal:  J Hum Genet       Date:  2011-06-02       Impact factor: 3.172

3.  Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients.

Authors:  Meng Chen; Jian Gu; George L Delclos; Ann M Killary; Zhen Fan; Michelle A T Hildebrandt; Robert M Chamberlain; H Barton Grossman; Colin P Dinney; Xifeng Wu
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

4.  Association of prostate cancer risk alleles with unfavourable pathological characteristics in potential candidates for active surveillance.

Authors:  Barry B McGuire; Brian T Helfand; Shilajit Kundu; Qiaoyan Hu; Jessica A Banks; Phillip Cooper; William J Catalona
Journal:  BJU Int       Date:  2011-11-11       Impact factor: 5.588

5.  GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes.

Authors:  Jingyao Dai; Jian Gu; Maosheng Huang; Cathy Eng; E Scott Kopetz; Lee M Ellis; Ernest Hawk; Xifeng Wu
Journal:  Carcinogenesis       Date:  2012-04-12       Impact factor: 4.944

6.  Racial disparities in the association between variants on 8q24 and prostate cancer: a systematic review and meta-analysis.

Authors:  Sarah M Troutman; Tristan M Sissung; Cheryl D Cropp; David J Venzon; Shawn D Spencer; Bamidele A Adesunloye; Xuan Huang; Fatima H Karzai; Douglas K Price; William D Figg
Journal:  Oncologist       Date:  2012-03-01

7.  NordicDB: a Nordic pool and portal for genome-wide control data.

Authors:  Monica Leu; Keith Humphreys; Ida Surakka; Emil Rehnberg; Juha Muilu; Päivi Rosenström; Peter Almgren; Juha Jääskeläinen; Richard P Lifton; Kirsten Ohm Kyvik; Jaakko Kaprio; Nancy L Pedersen; Aarno Palotie; Per Hall; Henrik Grönberg; Leif Groop; Leena Peltonen; Juni Palmgren; Samuli Ripatti
Journal:  Eur J Hum Genet       Date:  2010-07-28       Impact factor: 4.246

8.  Genome-wide association studies and beyond.

Authors:  John S Witte
Journal:  Annu Rev Public Health       Date:  2010       Impact factor: 21.981

9.  Discriminative accuracy of genomic profiling comparing multiplicative and additive risk models.

Authors:  Ramal Moonesinghe; Muin J Khoury; Tiebin Liu; A Cecile J W Janssens
Journal:  Eur J Hum Genet       Date:  2010-11-17       Impact factor: 4.246

10.  Testing for the recurrent HOXB13 G84E germline mutation in men with clinical indications for prostate biopsy.

Authors:  Florian R Schroeck; Kimberly A Zuhlke; Javed Siddiqui; Rabia Siddiqui; Kathleen A Cooney; John T Wei
Journal:  J Urol       Date:  2012-10-02       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.